Inito Secures $29M to Revolutionize At-Home Diagnostics with AI
December 14, 2025, 7:55 pm
Inito, a Bengaluru-based healthtech firm, just raised $29 million in Series B funding. This investment fuels expansion beyond fertility tracking. The company will develop AI-powered diagnostic tests for hormones, thyroid function, and metabolic health. Inito’s core innovation lies in synthetic antibody creation. This reduces reliance on traditional, slower methods. The funding signals growing investor confidence in AI-driven diagnostics. Expect faster, cheaper, and more accessible health insights. This move challenges conventional lab testing. It empowers consumers with personalized health data. Inito’s technology analyzes hormone data with precision. It offers a convenient alternative to clinic visits. The company has already analyzed over 30 million data points. It’s poised for significant growth in the consumer health market. This funding round was led by Bertelsmann India Investments. Fireside Ventures also participated. Inito’s future looks bright. It’s reshaping the landscape of preventative healthcare. The company aims to deliver lab-quality results at home. This is a major step towards democratizing healthcare access.
---
Inito, a rapidly growing healthtech company, secured $29 million in Series B funding. Bertelsmann India Investments led the round. Existing investor Fireside Ventures participated. This brings Inito’s total funding to $45 million.
The company plans to expand its diagnostic platform. It currently focuses on fertility. New tests will cover thyroid function, testosterone, and metabolic health. Inito’s core technology uses AI-engineered antibodies. This is a significant departure from traditional methods.
Traditional antibody development is slow and expensive. It relies on animal testing. Inito’s approach is faster and more precise. It utilizes computational protein design. This allows for the creation of synthetic antibodies. These antibodies offer higher sensitivity and consistency.
Inito’s device already tracks key fertility hormones. FSH, Estrogen, LH, and PdG are all monitored. AI algorithms analyze the data. They identify patterns and predict ovulation. The company has analyzed over 30 million hormone data points.
The funding will accelerate product development. It will also support expansion into new markets. Inito has teams in Dubai, Bengaluru, and London. The company holds over 20 patents.
Investor interest in at-home diagnostics is rising. Consumers want faster, cheaper, and more convenient options. Clinic visits can be time-consuming and costly. Inito offers a compelling alternative.
“The future of healthcare lies at the intersection of deep science, AI, and personal wellness,” stated Swati Murarka of Bertelsmann India Investments. Kannan Sitaram of Fireside Ventures highlighted Inito’s evolution. He called it a “trusted women’s health brand.”
Inito’s revenue growth slowed in FY25. It rose to Rs 67.6 crore. This is compared to a faster growth rate in FY24. However, the company began generating significant revenue in FY19.
Bertelsmann India Investments manages around $1 billion in assets. Its portfolio includes several prominent startups. Fireside Ventures is also a key player in the Indian venture capital landscape.
Inito’s success demonstrates the potential of AI in healthcare. It’s a prime example of how technology can improve access to care. The company is poised to disrupt the traditional diagnostics market. It’s offering a more personalized and convenient experience for consumers.
The shift towards at-home diagnostics is gaining momentum. Patients are increasingly empowered to take control of their health. Inito is at the forefront of this revolution. It’s building a future where healthcare is proactive and accessible to all. This funding round is a testament to Inito’s vision and potential. It’s a significant step towards a healthier future.
---
Inito, a rapidly growing healthtech company, secured $29 million in Series B funding. Bertelsmann India Investments led the round. Existing investor Fireside Ventures participated. This brings Inito’s total funding to $45 million.
The company plans to expand its diagnostic platform. It currently focuses on fertility. New tests will cover thyroid function, testosterone, and metabolic health. Inito’s core technology uses AI-engineered antibodies. This is a significant departure from traditional methods.
Traditional antibody development is slow and expensive. It relies on animal testing. Inito’s approach is faster and more precise. It utilizes computational protein design. This allows for the creation of synthetic antibodies. These antibodies offer higher sensitivity and consistency.
Inito’s device already tracks key fertility hormones. FSH, Estrogen, LH, and PdG are all monitored. AI algorithms analyze the data. They identify patterns and predict ovulation. The company has analyzed over 30 million hormone data points.
The funding will accelerate product development. It will also support expansion into new markets. Inito has teams in Dubai, Bengaluru, and London. The company holds over 20 patents.
Investor interest in at-home diagnostics is rising. Consumers want faster, cheaper, and more convenient options. Clinic visits can be time-consuming and costly. Inito offers a compelling alternative.
“The future of healthcare lies at the intersection of deep science, AI, and personal wellness,” stated Swati Murarka of Bertelsmann India Investments. Kannan Sitaram of Fireside Ventures highlighted Inito’s evolution. He called it a “trusted women’s health brand.”
Inito’s revenue growth slowed in FY25. It rose to Rs 67.6 crore. This is compared to a faster growth rate in FY24. However, the company began generating significant revenue in FY19.
Bertelsmann India Investments manages around $1 billion in assets. Its portfolio includes several prominent startups. Fireside Ventures is also a key player in the Indian venture capital landscape.
Inito’s success demonstrates the potential of AI in healthcare. It’s a prime example of how technology can improve access to care. The company is poised to disrupt the traditional diagnostics market. It’s offering a more personalized and convenient experience for consumers.
The shift towards at-home diagnostics is gaining momentum. Patients are increasingly empowered to take control of their health. Inito is at the forefront of this revolution. It’s building a future where healthcare is proactive and accessible to all. This funding round is a testament to Inito’s vision and potential. It’s a significant step towards a healthier future.